Radiopharm Theranostics Limited Sponsored ADR RADX 深 沪
已收盘 01-30 16:00:00 美东时间
5.05
+0.070
+1.41%
华盛通- 最 高5.05
- 今 开4.98
- 成交量 3.58万股
- 最 低 4.82
- 昨 收 4.98
- 总市值 3981.02万
- 52周最高 16.25
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 3.4962
- 委 比 -57.75%
- 总股本 788.32万
- 历史最高 50.82
- 量 比 1.55
- 振 幅 4.62%
- 历史最低 3.4962
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027
Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of
01-28 20:09
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics reported interim results from its Phase 2b clinical trial of RAD 101, with 92% of evaluable participants achieving MRI concordance. Additional interim data from Phase 1 trials of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. The company ended December 2025 with a cash balance of approximately $34.52 million, providing runway into 2027 to advance its pipeline. RAD 202 and RAD 204 showed promising sa...
01-28 12:00
Radiopharm Theranostics Raises Radiopharm Ventures Stake From 75% To 87.5% With Lead B7H3 Candidate Betabart Advancing Toward First Patient Dosing In Q1 2026
Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance
01-12 20:07
RAD Increases Ownership in Radiopharm Ventures to 87.5%
Radiopharm Ventures LLC, a joint venture between the University of Texas MD Anderson Cancer Center and Radiopharm Theranostics, was established in 2022. The company's lead candidate, Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase 1 therapeutic trial in multiple solid tumors, with the first patient expected to be dosed in Q1 2026. This marks the first global clinical trial targeting B7H3 with a systemic ...
01-12 12:00
Radiopharm Theranostics Announces Proposed Share Placement
Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Ra...
2025-12-18 12:12
Radiopharm Theranostics Addresses ASX Listing Rule Compliance Issue
Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Ra...
2025-12-18 11:32
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.
2025-12-16 00:59
Market-Moving News for December 15th
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With
2025-12-15 20:26
Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With MRI
The interim analysis showed that 92% (11/12) of the patients treated with RAD 101 achieved concordance with MRI (the primary endpoint) as assessed by PET imaging of brain metastases. The results showed significant and
2025-12-15 20:04
